22-11-2007: Genedata AG announced the establishment of a novel research IT alliance with Nycomed. An increasing number of pharmaceutical companies are outsourcing their research IT services to specialized partners in order to increase focus on their core competencies, drive IT innovation and subsequently improve IT performance and reduce overall R&D costs. In line with this trend and Nycomed`s new R&D operating model, Genedata and Nycomed are establishing a strategic partnership that will capitalize on Genedata`s extensive technological expertise to support Nycomed`s proprietary R&D data and knowledge management.
The existing Nycomed research IT infrastructure will be adapted to the new R&D operating model, with Genedata supporting Nycomed in developing and implementing scientific databases and applications for research data management and scientific analysis. The implementation of novel solutions and more efficient workflows is key in this effort. To enhance the smooth integration of Genedata's expertise into the R&D operations of Nycomed, Genedata has established an office on location, at the Nycomed site in Konstanz, Germany.
Watchlist
This is where you can add this news to your personal favourites
Genedata announced the extension of a biomarker discovery collaboration with Syngenta. Syngenta has added the Genedata Expressionist Refiner MS module for LC-MS and GC-MS metabolomic raw data processing and analysis to their existing Genedata Expressionist system. Refiner MS expands Expre ... more
Genedata, a provider of in silico solutions for the pharmaceutical and life science industries, and Axxam, a biotechnology research organization offering early-stage discovery research services for the life science industry, have signed a multi-year contract for the implementation of the Ge ... more
Genedata AG announced the establishment of a novel research IT alliance with Nycomed. An increasing number of pharmaceutical companies are outsourcing their research IT services to specialized partners in order to increase focus on their core competencies, drive IT innovation and subsequent ... more
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Ge ... more
Takeda Pharmaceutical Company Limited announced it has completed its acquisition of Nycomed A/S for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his ... more
Takeda Pharmaceutical Company Limited and Nycomed A/S jointly announced that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the company for 9.6 billion Euro on a cash-free, debt-free basis. The boards of directors of each company unanimously a ... more
Nycomed and Trenzyme extended their cooperation agreement for another four years. As a service provider for Nycomed, Trenzyme will continue handling projects ranging from DNA cloning, recombinant expression in E.coli, yeast and mammalian cells to protein purification and cell line developme ... more
With a broad portfolio of products and a powerful pipeline, we work in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.
We are engaged in all aspects of a product’s life, from research and development t ... more
Nycomed is a pharmaceutical company of 12,000 people united by a desire to improve the quality of patients’ lives. The company provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.
The company is act ... more
Nycomed is a pharmaceutical company of 12,000 people united by a desire to improve the quality of patients’ lives. The company provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.
The company is act ... more